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Asthma is a chronic, recurrent, and incurable allergy-related respiratory disease characterised 
by inflammation, bronchial hyper-responsiveness and narrowing of the airways. Extracellular 
vesicles (EVs) are a universal feature of cellular function and can be detected in different 
bodily fluids. Recent evidence has shown the possibility of using EVs in understanding the 
pathogenesis of asthma, including their potential as diagnostic and therapeutic tools. Studies 
have reported that EVs released from key cells involved in asthma can induce priming and 
activation of other asthma associated cells.  A literature review was conducted on all current 
research regarding the role and function of EVs in the pathogenesis of asthma via the PRISMA 
statement method. An electronic search was performed using EMBASE and PubMed through 
to November 2018.  The EMBASE search returned 76 papers while the PubMed search 
returned 211 papers. Following duplicate removal, titles and abstracts were screened for 
eligibility with a total of 34 studies included in the final qualitative analysis. The review found 
evidence of association between the presence of EVs and physiological changes characteristic 
of asthma, suggesting that EVs are involved the pathogenesis, with the weight of evidence 
presently favouring deleterious effects of EVs in asthma. Numerous studies highlighted 
differences in exosomal contents between EVs of healthy and asthmatic individuals, which 
could be employed as potential diagnostic markers. In some circumstances, EVs were also 
found to be suppressive to disease, but more often promote inflammation and airway 
remodelling.  In conclusion, EVs hold immense potential in understanding the pathophysiology 
of asthma, and as diagnostic and therapeutic markers. While more research is needed for 
definitive conclusions and their application in medical practice, the literature presented in this 
review should encourage further research and discovery within the field of EVs and asthma. 
































































Asthma is a chronic, recurrent, and incurable allergy-related respiratory disease 
characterised by inflammation, bronchial hyper-responsiveness and narrowing of the airways. 
An estimated 235 million people are afflicted by asthma worldwide, but it is often 
underdiagnosed and undertreated 1,2. Both environmental and genetic factors are involved in 
the pathogenesis of asthma 3,4. The immunohistopathologic features of asthma include 
granulocytic and lymphocytic infiltration, mast cell activation, and epithelial cell injury. In 
chronic cases, persistent changes in airway structure, including sub-basement fibrosis, mucus 
hypersecretion, injury to epithelial cells, smooth muscle hypertrophy, and angiogenesis, may 
occur. Interaction between diverse types of cells through mediators often result in airway 
inflammation and obstruction, as summarised in figure 1 5-8. 
Extracellular vesicles (EVs) are a universal feature of cellular function and can be 
detected in culture supernatants of different bodily fluids such as serum, broncho-alveolar 
lavage fluid (BALF), and nasal lavage fluid (NLF) 9. Due to these characteristics, there has 
been an increased interest in EVs and their potential applications in understanding the 
underlying mechanisms of various lung diseases, their use as biomarkers and therapeutic 
tools in lung inflammation 10. EVs are classified into three classes based on their biogenesis, 
secretory components, and size: exosomes, microvesicles (ectosomes), and apoptotic bodies 
11.
Exosomes are 50-150 nm EVs of endosomal origin. They contain enriched amounts of 
certain surface markers including tetraspanins, heat shock proteins, and MHC classes I and 
II. These components can be transferred to target cells either by direct membrane fusion, 
endocytosis, phagocytosis, or ligand interaction 12,13. Microvesicles (MVs) are larger than 
exosomes (100-2000 nm) and are derived from the plasma membrane of cells through direct 
outward budding. They contain substantial amounts of phosphatidylserine and membrane 
components as do their parent cells. Both exosomes and MVs contain elements which allow 
them to act as intercellular facilitators and release relevant signalling molecules 10,14. 
Apoptotic bodies are released from cells that undergo apoptosis and are usually 1-4 μm in 
diameter. They may contain DNA fragments, non-coding RNAs, and cell organelles 15.
Recent evidence has shown the possibility of using EVs in understanding the 
pathogenesis of asthma, including their potential as diagnostic and therapeutic tools. Methods 
such as ultracentrifugation and ExoQuick precipitation allow EVs to be isolated and studied in 
detail. Studies have reported that EVs released from key cells involved in asthma can induce 
priming and activation of other asthma associated cells. The production of these EVs can be 
regulated by pro-inflammatory and oxidative stress stimuli in vitro 16-18. For example, 
exosomes released from DCs containing costimulatory molecules and MHC class II can 
activate immune functions of Th2 cells within the lungs 19. 































































A multitude of research studies have investigated different pharmacological targets in 
asthma to better understand the pathophysiology of the disease and find novel treatments. 
In this respect, EVs have great potential, but there is currently insufficient research. In other 
respiratory diseases, EVs have already shown their potential. For example, microvesicles 
released from mesenchymal stem cells have been found to be cytoprotective in pulmonary 
fibrosis, a disease which is currently incurable 20. DC-derived exosome-based cell-free 
vaccines have shown success in eradicating established murine tumours 21. Much ongoing 
research exploring the potential of exosomes in chronic obstructive pulmonary disease 
(COPD), lung cancer, cystic fibrosis, primary ciliary dyskinesia, along with many others, is 
being conducted 22. This article reviews all available research on EVs in the pathogenesis of 
asthma to identify existing knowledge and promote further research within the field. 
Highlighting hypotheses and noteworthy results from current literature also underlines the 
limitations of past studies, for future improvements.  The specific research question we 
address is whether there is currently sufficient evidence to support pro-inflammatory, airway 
remodelling and/or protectives roles of cell-derived EVs in asthma.
2 METHODOLOGY
2.1 Sources and Searches 
For this review, the PRISMA statement method was implemented. An electronic search 
was performed using EMBASE and PubMed (results up to November 2018).  
The search term for EMBASE was
((Exosome* or "Extracellular vesicles" or "extracellular vesicle" or Microvesicle* or 
ectosome* or "shedding vesicle" or "shedding vesicles" or microparticle) and (asthma* 
or "type 1 hypersensitivity" or allergy* or bronchospasm* or "status 
asthmaticus")).mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword, floating 
subheading word, candidate term word]
and the search term for PubMed was 
((Exosome* or "Extracellular vesicles" or "extracellular vesicle" or Microvesicle* or 
ectosome* or "shedding vesicle" or "shedding vesicles" or microparticle) and (asthma* 
or “type 1 hypersensitivity” or allergy* or bronchospasm* or “status asthmaticus”))
2.2 Study Selection
The aim of this review was to combine and interpret all current research on the role 
and functions of EVs of known cellular origins in the pathogenesis of asthma. Only primary 
research literature has been included. Research that was either unpublished or published in 































































non-peer reviewed forms (including abstracts and conference proceedings) were not included.  
Studies concerning exosomes derived from microorganisms and their effects in asthma were 
also excluded.
3 FINDINGS
3.1 Results of PRISMA statement Evidence Search and Selection
The EMBASE search returned 76 papers, while the PubMed search returned 211 
papers. Search results were imported using the reference manager, ENDNOTE, to find and 
exclude duplicates. After duplicates were removed (reducing the number to 260), titles and 
abstracts were then screened for relevance to the research question: this led to further 
exclusions due to lack of relevance (e.g. wrong type of ‘microparticles’) or because 
publications were reviews rather than primary research (records excluded n = 197). 
The remaining 63 studies were eligible for a full text review. A further 29 studies were 
excluded using inclusion and exclusion criteria (table 1). A total of 34 studies were included 
in the final qualitative analysis (figure 2).  The first study was published in 2001, with numbers 
of publications increasing yearly until 2018, when nine studies were published (figure 3).  
There were not enough studies addressing very similar research questions to allow a meta-
analysis of data to be conducted.
3.2 Extracellular Vesicles of Known Cellular Origin
Twenty-one studies found that EVs of known cellular origin are associated with 
asthma and allergic inflammation. Of these, four studi s investigated EVs derived from 
eosinophils, three from mast cells, three from mesenchymal cells, two each from T-cells, 
DCs and epithelial cells, and one each from myeloid-derived regulatory cells, neutrophils, 
platelets, B-cells and fibroblasts (figure 4).
3.2.1 Mast cell-derived Extracellular Vesicles (Table 2)
Mast cells release histamine, prostaglandins, leukotrienes, and other inflammatory 
mediators which are capable of inducing an asthma attack 23. Three studies have reported 
that exosomes from mast cells are associated with asthma and the lung inflammatory 
response. Skokos et al. 24 found that bone marrow-derived mouse mast cells (BMMC) and 
mast cell lines P815 and MC9-derived exosomes carried immunologically relevant molecules 
(i.e. MHC class II, LFA-1, ICAM-1 and CD86). The results indicated that these BMMC exosomes 
can induce splenic B and T cell blast activation without physical contact between the cells. 
This suggests that exosomes from mast cells may play a role in the recruitment of B and T 
cells to the lungs 24.  On the other hand, Xie et al. 25 reported that mast cell exosomes 































































containing high-affinity IgE receptors (FcεRI) can suppress allergic reactions by binding to 
free IgE. The study demonstrated that exosomes derived from BMMCs, which can bind to free 
IgE via FcεRI, possess anti-IgE effects, decrease IgE levels and inhibit mast cell activation 25. 
The third study by Eldh et al. 26 suggests that mast cell-derived exosomes may have a 
protective effect on the oxidative stress of the lungs during an inflammatory response. The 
study established that exosomes released by mouse mast cells exposed to oxidative stress 
differ in their mRNA content and can influence the response of other cells to oxidative stress 
by providing the recipient cells with resistance. 
3.2.2 Eosinophil-derived Extracellular Vesicles (Table 2)
Eosinophils are often found in severe types of asthma and are amongst the main 
effector cells in the disease. Elevated levels of eosinophils are found to cause airway 
inflammation and breathlessness 27,28. Four trials suggested that exosomes from eosinophils 
are associated with asthma and the lung inflammatory response (Table 2). Mazzeo et al. 29 
investigated exosome secretion by eosinophils. Exosomes were purified from eosinophils in 
the peripheral blood of asthmatic and healthy subjects. Results confirmed the secretion of 
exosomes by eosinophils and found that interferon-gamma (IFN-γ) stimulation led to an 
increase in the production of exosomes. Furthermore, they demonstrated that the production 
of exosomes was augmented in asthmatic patients 29.  Akuthota et al. 30 also investigated EVs 
released by eosinophils of allergic and healthy donors. They confirmed that eosinophils 
produced EVs under physiological conditions, and that exposure of eosinophils to CCL11 
(which stimulates IL-4 production) and TNF-α (which stimulates of IL-4, IL-6 and IFN-γ 
production) increased EV formation. 
Canas et al. 31 reported that the amount of exosome production was greater from 
eosinophils of asthmatic patients compared to healthy individuals. The rate of apoptosis of 
eosinophils of asthmatic patients was also reduced compared to healthy participants. The 
exosomes increased eosinophil production of ROS and NO, and promoted chemotaxis and 
adhesion of eosinophils. This suggests that eosinophil-derived exosomes can promote the 
inflammatory behaviour of eosinophils that is associated with asthma.  Another study by the 
same group 32 demonstrated that eosinophil-derived exosomes participate in the pathological 
processes of asthma by activating structural lung epithelial cells and bronchial smooth muscle 
cells (BMSC). The results indicated that epithelial cell wound healing processes are reduced 
in the presence of eosinophil-derived exosomes due to increased apoptosis of epithelial cells. 
Analysis of epithelial cell gene expression also showed increased expression of TNF, CCL26 
and POSTN (periostin) genes which represent an asthma-specific mRNA signature 33. 
Hyperplasia and hypertrophy of bronchial smooth muscle cells (BMSC) is thought to be part 
of the pathophysiology of the process. Data from the study showed significantly increased 































































proliferation of BMSCs when co-cultured with exosomes from eosinophils of asthmatic 
patients, as well as increased gene expression of CCR3 and VEGF A which are associated to 
angiogenesis and fibrotic processes 32. In summary, the study shows significant involvement 
of eosinophil-derived exosomes in the pathophysiology and disease progress of asthma.
3.2.3 Neutrophil-derived Extracellular Vesicles (Table 2)
Although asthma has been classically associated with eosinophils, newer research has 
found that neutrophils may also play a role in the inflammation and airway remodelling of 
asthmatics, especially in severe cases 34-37. Vargas et al. 37 investigated whether exosomes 
are released by neutrophils and evaluated their abilities in modulating airway smooth muscle 
cell proliferation in an equine model. The study concluded that exosomes released from 
activated neutrophils could promote growth of airway smooth muscle cells, indicating the 
potential for their role in airway remodelling in asthma patients 37. 
3.2.4 B cell-derived Extracellular Vesicles (Table 3)
B-cells play a crucial role in the sensitization and adaptive immune response of asthma 
38-41. Admyre et al. 42 concluded that B cell-derived exosomes play a role in stimulating the 
allergic immune response. Exosomes isolated from B cells can present allergen-derived 
peptides to induce T-cell proliferation and production of Th2-like cytokines. B cells were 
isolated and transformed from four donors with a history of hay fever. B cell–derived 
exosomes were then loaded with biotinylated or un-biotinylated birch peptides, Bet v 1 
peptides, Bet v 14-18, and/or Bet v 1142-156. The supernatant was analysed for a variety of 
inflammatory mediators. The results showed B cell–derived exosomes’ ability to bind peptides 
derived from Bet v 1, induction of Bet v 1 peptides specific T-cell proliferation and induce 
cytokine production of allergen-specific T cells (IL-4, IL-5, and IL-13 and lower levels of IFN-γ 
and TNF-α) 43. The mechanism by which B-cells-derived exosomes activate T-cells is still 
under debate, but some studies suggest that exosomes can stimulate T cells directly 42,44 
whereas others demonstrate that exosomes need the presence of antigen presenting cells to 
exert their effects 45,46. 
3.2.5 T cell-derived Extracellular Vesicles (Table 3)
Th2 cell-derived inflammation, leading to airway responsiveness and tissue 
remodelling, is one way asthma can be characterized 47-50. Two studies show that exosomes 
from T-cells are associated with asthma and the lung inflammatory response. A study by 
Shefler et al. 51 concluded that T cell EVs carry similar signalling molecules to their cells of 































































origin and can induce mast cell degranulation and cytokine release. Activated T cells can 
utilize these EVs to facilitate the activation of mast cells at distant inflammatory sites. The 
study suggested that blocking the release of these MVs may serve as a therapeutic target. In 
a more recent study, the same authors 52 reported that T-cell derived MVs carry miR-4443, 
which might exert heterotypic regulation of protein tyrosine phosphatase receptor type J gene 
expression in mast cells causing mast cell activation. 
3.2.6 Dendritic cell-derived Extracellular Vesicles (Table 3)
Dendritic cells (DCs) play a central role in sensing the presence of foreign antigens 
and infectious agents and presenting them to T cells. DCs also regulate the activation of 
allergic pathways in response to potential environmental allergens. Significant increases in 
the numbers of airway DCs have been reported after exposure to allergen and can lead to an 
inflammatory response 53. Two studies have shown that exosomes derived from DCs play a 
similar role to DCs themselves in promoting asthma. A study by Vallhov et al. 19 explored 
whether DC-derived exosomes can present the major cat allergen Fel d 1 and contribute to 
the pathogenesis of allergic disease. Exosomes were isolated from monocyte derived DCs of 
cat-allergic donors that had been cultured alone, or co-cultured with Fel d 1. It was found 
that DCs could distribute aeroallergens via exosomes, and that these exosomes could present 
the allergen and induce Th2-like cytokine production. 
A study by Wahlund et al. 54 investigated the immunostimulatory potential of both MVs 
and exosomes derived from ovalbumin (OVA)-pulsed DCs. Exosomes and MVs were isolated 
from OVA-pulsed murine bone marrow-derived DCs and were injected into recipient mice. 
The results indicated that both exosomes and MVs were equally enriched in 
immunostimulatory molecules, as seen by the surface expressions of MHC class I, class II, 
and costimulatory molecules CD40, CD80, CD86, and CD54. However, the ability to activate 
OVA-specific CD8+ T cells was exclusive to exosomes. Exosomes also induced higher levels 
of OVA-specific IgG antibodies compared to MVs. The study suggested that the superior ability 
of exosomes to induce OVA-specific T cell responsiveness was because OVA was enriched in 
exosomes, but could hardly be detected in MVs.         
3.2.7 Myeloid-derived regulatory cell Extracellular Vesicles (Table 3)
Free radical generating myeloid-derived regulatory cells (MDRC) are known to regulate 
activities of T-cells and airway responses in asthma 55,56. While most previous research has 
focussed on mechanisms of communication through oxidant pathways and soluble mediators, 
a study by Hough et al. has found that exosome-mediated intercellular transfer could also be 
a mechanism by which MDRCs in asthmatics can communicate with T cells and signal T-cell 
proliferation 57. Since mitochondria are capable of secreting ROS and play a role in the 
inflammatory response, the study aimed to measure mitochondrial transfer in exosomes 
derived from MDRCs of asthmatics. The study reported that EVs isolated from airways of 































































asthmatic patients contain higher levels of mitochondrial DNA. This suggests a potential 
source of pro-inflammatory signalling by MDRCs of the respiratory system. The study also 
reported evidence of MDRC-to-T cell transfer of mitochondria packaged within exosomes. 
3.2.8 Platelet-derived Extracellular Vesicles (Table 3)
Platelet microparticles (PMP) make up the largest fraction of circulating EVs and are 
elevated in many systemic diseases such as rheumatoid arthritis, cancer, diabetes, and acute 
coronary syndrome 58,59. Furthermore, it has been found that platelets are associated with 
airway hyper‐responsiveness and bronchial remodelling 58-60. Duarte et al. 61 found that 
circulating levels of PMP are significantly increased in asthmatic subjects.           
3.2.9 Epithelial cell-derived Extracellular Vesicles (Table 4)
Airway epithelial cells play a pivotal role in the pathogenesis of asthma as a primary 
airway defence against exposure to inflammatory stimuli and antigens. Activation of epithelial 
Toll-like receptors (TLRs) provides an important link between innate immunity and allergic 
diseases 62. Epithelial cells can also promote inflammation by directing DCs to drive a Th2 
response 63. Two studies have addressed the role EVs derived from airway epithelial cells in 
the pathogenesis of asthma.
A study by Kulshreshtha et al. 64 found that murine epithelial cell–derived exosomes 
can induce proliferation and infiltration of undifferentiated macrophages into the lungs under 
the influence of IL-13 released during asthmatic inflammatory conditions. The study 
established bronchial epithelial cells as a major source of exosomes during acute airway 
inflammation. Bronchial epithelial cell-derived exosomes were also found to induce 
proliferation and chemotaxis of undifferentiated macrophages. 
Another study conducted by Park et al. 65 aimed to determine potential sources of 
tissue factor (TF), a primary initiator of blood coagulation, and the mechanisms of its 
availability in the lung micro-environment. Airway expression of TF can be associated with 
asthma as the disease is characterized in part by sub-epithelial angiogenesis. The results 
established that compressive mechanical stress induces TF mRNA expression and intracellular 
TF protein, as well as TF-bearing exosomes in well-differentiated normal human bronchial 
epithelial cells. This confirms the ability of exosomes to translocate TF from one cell type to 
another by vesicle trafficking 65.































































3.2.10 Fibroblast-derived Extracellular Vesicles (Table 4)
By regulating the functions of bronchial epithelial cells, bronchial fibroblasts play a key 
role in the structural changes which occur in asthma 66,67. A study by Haj-Salem et al. 68 
evaluated the role of bronchial fibroblast-derived exosomes on epithelial cell proliferation in 
severe asthma. Exosomes were purified from fibroblasts of healthy subjects and severe 
asthmatic subjects and co-cultured with bronchial epithelial cells. The results revealed no 
difference in exosome release efficiency between fibroblasts of healthy controls and severe 
eosinophilic asthmatic subjects; however, TGF‐β2 levels, which significantly reduced 
proliferation of epithelial cells, were significantly lower in exosomes of severe asthmatics. 
Consistent with this, exosomes derived from fibroblasts of the severe asthmatic subjects 
enhanced epithelial cell proliferation, whereas fibroblast‐derived exosomes from healthy 
controls significantly decreased the proliferation rate. 
3.2.11 Mesenchymal stem cell- and Mesenchymal cell-derived Extracellular Vesicles (Table 
4)
Mesenchymal stem cells (MSC) are pluripotent stromal cells which differentiate into a 
variety of mesenchymal cell types including osteocytes, myocytes, and adipocytes. Previous 
studies have shown that MSCs can reduce asthma airway inflammation by up-regulating the 
proliferation of Treg cells 69,70. Three studies have investigated the role of mesenchymal stem 
cells or stromal cells in airway remodelling in asthma patients. A study by Du et al. 71 found 
that that MSC-derived exosomes can promote immunosuppression in asthmatics by 
upregulating IL-10 and TGF-β1, which results in regulatory T-cell (Treg) proliferation. 
Exosomes from human bone-marrow derived MSCs of healthy adults were co-cultured with 
peripheral blood mononuclear cells (PBMC) of asthmatic patients. Increased concentrations 
of IL-10 and TGF-β1 were found in the exosome-PBMC co-cultures, although even higher 
concentrations were observed in MSC-PBMC co-cultures. 
De Castro et al. 72 demonstrated that adipose tissue mesenchymal stromal cells and 
their EVs reduced eosinophil counts in mouse lung tissue and bronchoalveolar lavage fluid 
(BALF), as well as modulating airway remodelling. In a third study, Cruz et al. 73 found that 
systemic administration of EVs from bone marrow‐derived mesenchymal stromal cells was as 
effective as their cells of origin in suppressing Th2/Th17‐mediated airway hyper-
responsiveness and lung inflammation in a model of Aspergillus-hyphal extract-induced 
allergic airway inflammation. 































































3.3 Extracellular vesicles in body fluids 
3.3.1 Bronchoalveolar lavage fluid-derived Extracellular Vesicles (Table 5)
Eight studies have investigated the role of exosomes derived from BALF in the 
pathogenesis of asthma. A study by Hough et al. 74 compared the lipid composition and 
presence of specific lipid mediators in airway EVs purified from the BALF of healthy controls 
and asthmatic subjects. The results indicated elevated concentrations of EVs in the BALF of 
asthmatic subjects and that the increase correlated with blood eosinophilia. They also found 
extensive differences in lipid composition between the EVs of the asthma group and controls. 
Lipids such as ceramides, ceramide-phosphates, phosphatidylglycerol, and sphingomyelins, 
which are mediators of inflammation in asthma were found to be increased in EVs derived 
from asthma patients 74. 
A study by Rollet-Cohen et al. 75 used proteomics to compare respiratory exosomal 
contents isolated from BALF of patients suffering from cystic fibrosis (CF), primary ciliary 
dyskinesia (PCD) and asthma. Exosomes from asthma patients contained lower amounts of 
grancalcin and histones, contained Serpin A6, a protein involved in counter regulation of 
immune proteinases, and APOA4, a protein playing a role in lipid and surfactant metabolism. 
Most proteins identified are known activators of the NFκB pathway and can contribute to the 
pro-inflammatory status of these respiratory diseases 75. 
Torregrosa Paredes et al. 76 explored the phenotypic and functional characteristics of 
BALF exosomes in asthma and investigated whether these exosomes have leukotriene 
biosynthetic capacity. BALF exosomes were collected and purified from healthy individuals 
and patients with mild allergic asthma to birch pollen before and after birch allergen 
provocation. The results showed that the BALF exosome profile was altered in asthmatics and 
had increased expression of HLA‐DR. Incubation of BALF exosomes with human bronchial 
epithelial cells showed that exosomes from asthmatics induced significantly higher levels of 
LTC4 and IL‐8 release compared to exosomes from healthy individuals. The data suggest that 
exosomes from BALF of asthmatics can induce pro-inflammatory cytokines and LT responses 
from airway epithelial cells which could potentially contribute to inflammation in asthma. 
Levänen et al. 78 found a significant difference in BALF exosomal miRNA between 
mild asymptomatic asthmatic subjects and healthy subjects. The study found that, at 
baseline, the expression profile of the altered miRNAs was highly correlated with lung 
function (FEV1) in the asthma group. 
Wan et al. 77 investigated the effects of EVs from healthy mouse lungs in regulation 
of the immune balance in the respiratory tract. They found that, among the subsets of EVs, 
CD8α+CD11c+ EVs contain immunosuppressive cytokines TGF-β1 and IL-10. These 































































cytokines could inhibit T helper cell proliferation via TGF-β1 in vitro and relieve asthmatic 
symptoms in mice. However, even independent of these two cytokines, the EVs were 
effective at inhibiting OVA peptide–specific CD4+ T cell proliferation. Furthermore, they 
could also prevent T helper cells from secreting IL-4, IL-9, and IL-17A via IL-10 ex vivo. 
A study by Prado et al. 79 demonstrated that BALF-derived exosomes from tolerized 
mice could prevent an allergic reaction. Female mice were tolerized by respiratory exposure 
to the olive pollen allergen Ole e 1. Exosomes were then isolated from BALF of these mice 
as well as naïve mice as controls. The results showed that tolerogenic exosomes inhibited 
specific IgE and IgG1 in an allergic sensitization model, and that pre-treatment with 
tolerogenic exosomes inhibited Th2 cytokines, but induced TGF-β. Tolerogenic exosomes 
were also found to reduce allergen-induced airway inflammation in mice. 
A subsequent study by the same authors 80 investigated whether such exosomes 
generated in response to Ole e 1 could also prevent the sensitization to other unrelated 
allergens, such as Bet v 1 from birch pollen. Exosomes were isolated from BALF of Ole e 1 
tolerized mice using the same methods as in the previous study. The results suggest that pre-
treatment with tolerized exosomes specific to Ole e 1 could also block allergic responses to a 
second unrelated allergen such as Bet v 1. 
Gon et al. 81 analysed variations in the production of airway EVs and their miRNA 
content in a house‐dust mite (HDM) allergen‐exposed murine asthma model. Airway EVs from 
BALF of mice were isolated using the ExoQuick Exosome Precipitation Solution. Compared to 
the usual technique of ultracentrifugation, this provides a higher extraction efficiency but has 
the risk of protein contamination when used to isolate exosomes in cell culture media 82. The 
results showed that the amount of EVs observed increased by 8.9-fold in the BALF of 
HDM‐exposed mice compared to the control group. After exposure to HDM, significant changes 
in the expression of 139 miRNAs in EVs were also recorded. 
Shin et al. 83 evaluated the role of EVs in the development of airway immune 
dysfunction in response to LPS inhalation. EVs in BALF of mice were isolated after exposure 
to LPS. The results showed that inhalation of LPS enhanced EV release into the BALF. 
Furthermore, airway sensitization with allergens and LPS-induced EVs resulted in a mixed 
Th1/Th17 cell responses and enhanced production of Th1/Th17-polarizing cytokines (IL-
12p70 and IL-6) by lung DCs. While not directly correlated to asthma, the study provides 
evidence that exosomes play a role in immune responses to allergens within the lungs. 































































3.3.2 Serum-derived Extracellular Vesicles (Table 6)
Two studies have reported that exosomes derived from serum could potentially be 
involved in the pathogenesis of asthma. Almqvist et al. 84 provided evidence that 
serum‐derived exosomes from OVA-fed mice could prevent allergic sensitization in a model 
of allergic asthma. The transfer of serum exosomes from OVA-fed mice reduced eosinophil 
levels and antigen-specific IgE.  Gao et al. 85 examined the effects of circulating MVs on airway 
smooth muscle function and found that exposure to circulating MVs of asthma patients, at a 
concentration that matched their plasma levels, reduced endothelium-dependent relaxation 
to bradykinin and increased contraction to acetylcholine in mouse trachea. These results 
suggest circulating MVs might be involved in the underlying mechanisms of airway smooth 
muscle dysfunction.
3.3.3 Nasal lavage fluid-derived Extracellular Vesicles (Table 6)
Lässer et al. 86 examined the proteome of NLF-derived exosomes in healthy subjects, 
as well as its alterations in individuals with asthma and chronic rhinosinusitis. Serum-
associated proteins and mucins were increased in the exosomes from individuals with 
respiratory diseases compared to healthy controls, whereas proteins with antimicrobial 
functions and barrier-related proteins showed decreased expression. 
3.3.4 Exhaled breath condensate-derived Extracellular Vesicles (Table 6)
Sinha et al. 87 demonstrated how miRNAs could be reliably detected in exhaled breath 
condensate (EBC) using quantitative PCR analysis. RNA was extracted from vacuum-dried and 
concentrated EBC samples of asthmatic and healthy subjects. It was found that miRNAs 
present in EBC are mainly associated with exosomes. The EBC miRNA profile of asthmatic 
patients differed from that of healthy controls, with some of the identified miRNAs known to 
be associated with asthma, allergy, and inflammatory pathways.
4 DISCUSSION
4.1 Main Findings
The investigation of the biological role of EVs in lung disease has become a rapidly 
progressing field. The role of EVs as intercellular messengers and the possibility that they 
could serve as novel diagnostic or pharmacological targets has made this an exciting field. 
The aim of this review was to combine and interpret all current research on the role and 
functions of EVs in the pathogenesis of asthma and, in particular, assess the weight of 
evidence for specific roles of EVs in asthma. Data from the studies included in this review 
provide evidence that EVs, including exosomes and MVs, may play important roles in the 
pathogenesis of asthma and airway inflammation. 































































4.1.1 Findings for Extracellular vesicles of known cellular origins 
One objective of the review was to identify all current research on EVs of known cellular 
origin in asthma. Understanding the effects of EVs and associating them with their cellular 
origin helps establish specific pathways and cellular networks for EVs within the context of 
asthma. While the general pathophysiology of asthma is quite well understood, the role of 
EVs in this complex network between immune and local cells has yet to be clarified. Most 
research presented in this review concluded that EVs, particularly exosomes, are heavily 
implicated in the pathogenesis of asthma. This delineates how cells can interact with each 
other without direct physical contact. Table 7 provides a summary showing that EVs from 
numerous cell types can stimulate pro-inflammatory responses, a key aspect of the patho-
physiology of asthma. Four studies show that EVs derived from eosinophils, neutrophils, 
epithelial cells and fibroblasts can trigger ASM cell remodelling. In contrast, some other 
studies demonstrate that EVs from mast cells and MSCs can be used defensively in reducing 
inflammation and oxidative stress in asthma.  Overall, fourteen studies provided evidence 
that EVs derived from specific cell types may have pro-inflammatory or airway remodelling 
effects in asthma, whereas just five indicate protective effects.  The weight of evidence is 
therefore in favour of deleterious effects of EVs in asthma, at the present time. However, 
whilst the studies presented in this review indicate that EVs have a profound impact on the 
pathogenesis of asthma, the number of studies representing each cell type is limited, and 
further research is required before firm conclusions can be drawn.  This applies particularly 
to determining whether EVs from particular cell types are primarily deleterious or protective 
in the pathogenesis of asthma: for example, the current evidence for mast cell-derived EVs 
is mixed 24-26, whereas the all the current evidence for mesenchymal stem cell-derived EVs 
indicates that they are protective 71-73. 
4.1.2 Findings for Extracellular Vesicles from body fluids 
Many of the studies suggest that the composition of EVs and their contents are variable 
and can be altered depending on specific conditions. EVs of asthma patients often contain 
pro-inflammatory proteins, lipids and cytokines such as Serpin A6, LTC4, tetraspanins CD81, 
IL-6, and IL-8, amongst others. In contrast, EVs of healthy individuals obtained from BALF 
contain immunosuppressive cytokines such as TGF-β1 and IL-10, which are thought to play 
a role in immune regulation. This suggests that dysfunction within the exosomal system and 
changes in exosomal contents are associated with the development of asthma. Understanding 
the differences in exosomal contents between asthmatic and healthy individuals may clarify 
their role in asthma and their potential as a diagnostic or monitoring tools.  Currently, there 
are insufficient studies to allow firm conclusions to be drawn; there is also the issue of 
uncertainty in the extent to which findings in animal models may be applicable to asthma in 
humans.          































































4.1.3 The therapeutic potential of Extracellular Vesicles 
An interesting aspect of exosomes is their potential in inducing tolerance and 
protection against allergic sensitisation; this provides the possibility for the development of 
novel vaccines. Three studies demonstrated how mice receiving tolerizing exosomes from 
other allergen-challenged mice showed reduced specific IgE and IgG1 79, 80, 84. Pre-treatment 
with tolerogenic exosomes also inhibited Th2 cytokine production and induced TGF-β, showing 
their capacity in limited allergic sensitization. Furthermore, the effects were long lasting, and 
receiving exosomes tolerized with one allergen, can inhibit the sensitization to other allergens.
Overall, whilst the evidence is not strong currently, nine studies concluded that EVs 
may be implicated as a therapeutic tool, mostly to reduce inflammation in patients suffering 
from asthma. EVs isolated from different sources, including mesenchymal cells 71-73, mast 
cells 25, 26, BALF 79, 80 and serum 84 mitigate allergic airway inflammation through various 
mechanisms such as reducing eosinophil count, reducing the amount of free IgE, promoting 
proliferation of Treg cells, and increasing mucosal tolerance to sensitization.
4.1.4 The diagnostic potential of Extracellular Vesicles 
Whilst many studies demonstrate measurable differences between the characteristics 
of EVs in healthy and asthmatic patients, the difficulty of using EVs as diagnostic tools is 
justifying the use of invasive procedures required to obtain the EVs. Currently, the diagnosis 
of asthma is clinically based, and does not require invasive procedures such as 
bronchoalveolar lavage 78 or blood tests 86 to confirm the diagnosis. However, novel non-
invasive methods, such as using exhaled breath condensate to obtain EVs 87, may be useful 
in helping to classify the severity of the disease and predict the prognosis. Clearly, 
evaluating the potential value of EVs as biomarkers of asthma requires studies involving a 
much more detailed comparison of EVs with other biomarkers that are already well-
characterized and available. In addition, studies are required to investigate the relationship 
between particular types of EVs and different phenotypes and endotypes of asthma that 
have been characterized.
4.2 Limitations and future research. 
Heterogeneity within the research reviewed here should be considered. The studies 
adopted various experimental designs from in vitro studies of human cells, in vitro studies 
of murine cells, in vitro studies of equine cells to in vivo studies in mice. Differences in 































































development, gene regulation and expression, genomics, and epigenetics between each 
species should be considered before extrapolating the results to humans 88. Furthermore, 
the numbers of subjects (patients and controls) is also critical in assessing the confidence 
with which conclusions can be made: most of the studies discussed in this review employed 
relatively low numbers of patients or healthy controls (≤ 20), with some having only 3 or 4 
subjects.  The highest number was in a study employing 58 asthmatic subjects and 16 
healthy volunteers to study exosomes derived from eosinophils 31.  Thus more studies with 
larger numbers of subjects are required in order to consolidate confidence in the findings 
reported.  The heterogeneity of patients in terms of the representation of different 
phenotypes and endotypes of asthma within the subject populations should also be 
considered.  
Due to the relatively small number of currently available studies in each area of 
research, the results and findings presented must be interpreted with caution. Thus, further 
studies are required to consolidate the evidence that is currently available. Every area 
presented in this review potentially needs more research to be conducted; however, some 
areas hold more promise than others. For example, additional research on the differences in 
exosomal contents or levels between asthmatic and healthy subjects could help to develop a 
novel, non-invasive diagnostic tool for asthma, particularly by investigating EVs in exhaled 
breath 87. The role of EVs in preventing allergic sensitisation is also a fascinating area with 
the potential for developing preventative or prophylactic medicines; however, it is likely to be 
a significant time before such studies can move from animal models to patients. Because 
myriads of cells within the body can produce exosomes, each containing distinct constituents, 
the possibility for further research is considerable. 
A further area for research is likely to be the effects of allergen desensitization 
interventions on the nature and constituents of EVs as this could provide further insights into 
the relationship between EVs and asthmatic status.
Overall the studies conducted so far on EVs in relation to asthma indicate that they 
are significant factors in the disease, but much further research is required to consolidate and 
expand on these findings.
Data sharing  Data sharing is not applicable to this article as no new data were created or 
analyzed in this study.
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Table 1. Inclusion and Exclusion Criteria Used for Study Selection
Inclusion Criteria Exclusion Criteria
Experiment involving the extraction, 
identification, or production of extracellular 
vesicles or their contents (eg. miRNA) 
Experiment involving lung disease but not 
specifically asthma (eg. COPD, lung cancer, 
bronchitis, primary ciliary dyskinesia)
Experiment involving asthma, inflammatory 
lung diseases, allergic airway diseases, or 
any other diseases closely related to asthma 
within the respiratory tract
Experiment involving allergic inflammation 
but not in the lungs (eg. eczema)
Full text must be available in English Non-primary studies (eg. reviews)
Isolation method of EVs must be given if 
applicable









































































Nonspecific B and T 
cell-stimulatory 
activity mediated by 
mast cells is 
associated with 
exosomes
Investigate whether mast 
cell-derived exosomes can 
stimulate B and T 




Exosomes act as complex 
messengers of mast cells for 
intercellular communication within 
the immune system.
Xie et al. 
2018 [25]
Mast cell exosomes 
can suppress 
allergic reactions by 
binding to IgE 
Explore whether 
extracellular exosomes 




By binding to free IgE via FcεRI, 
mast cell exosomes can regulate 
multiple physiology of asthma 
including airway inflammation, 
airway hyperresponsiveness, and 
some parts of airway remodeling.
Eldh et al. 
2010 [26]




cells with protection 
against oxidative 
stress
Investigate whether mast 
cell-derived exosomes 
obtained under variable 




RNA enclosed in exosomes provide 
recipient cells with protection 
against external stress stimuli and 







by eosinophils: A 
possible role in 
asthma progression
Characterize eosinophil 
derived exosomes and 




MVs and exosomes produced and 
secreted by eosinophils possibly 












Identify and characterize 
EVs released from human 
eosinophils after a culturing 
period or after isolation and 




Human eosinophils increase MVs 












exosomes can autoregulate 




Exosomes from the eosinophils of 
asthmatic patients can modify 
several specific eosinophil 











Investigate whether the 
activation of structural lung 
cells leading to asthma 
pathogenesis can be the 





Eosinophil-derived exosomes from 
asthmatic patients participate 
actively in the development of the 














exosomes, and if so identify 
the proteomic profile and 
evaluate their capacity to 





stimulated by LPS could play an 
central role in the progression of 
asthma through inducing the 
proliferation of ASM cells and 
promoting airway remodeling in 
severe and corticosteroid-
insensitive asthma patients.































































Table 3. Summary of study on exosomes derived from B cells, T cells and dendritic 











exosomes can present 
allergen peptides and 
activate allergen-




Investigate whether B cell-
derived exosomes is 
involved in allergen 




B cells exosomes can induce T-cell 
proliferation and Th2-like cytokine 







T cell-induced mast 




Investigate whether T cell 
MVs can lead to mast cell 
activation by imitating the 
functions of their origin cell.
in 
vitro
T cells release MVs containing 
mast cell-activating factors similar 
to the origin cell and can convey 
surface molecules to emulate 







regulates mast cell 
activation by T cell-
derived microvesicles
Characterize the 
contribution of microRNAs 
delivered by microvesicles 
to mast cell activation.
in 
vitro
In the context of T cell-mediated 
inflammation, T cell-derived MVs 
can carry functional miR-4443 that 







exosomes carry the 
major cat allergen Fel 
d 1 and induce an 
allergic immune 
response 
Explore the possibility of 
Fel d 1 presentation by DC-
derived exosomes and 
whether this is responsible 




Exosomes are able to present 
aeroallergens and thereby induce 
T-cell Th2-like cytokine production 














potential of OVA-pulsed 




While both MVs and exosomes 
derived from DCs can activate an 
immunostimulatory response, 
exosomes are more potent and 
should be considered and 











cells to T cells
Investigate the intercellular 
transfer of bioactive 




Mitochondria co-localize with the 
mitochondrial network enclosed in 
MDRC-derived exosomes support 
intercellular direct exosome-
mediated transfer and can 









as a potential 
biomarker in asthma
Determine the levels of 




PMPs may play a role in asthma 
pathophysiology as a possible 
asthma biomarker.
   































































Table 4. Summary of studies on exosomes derived from epithelial cells, fibroblasts 
and mesenchymal stem cells.
Author, 
Year [Ref] Title Aim Type Conclusion
Epithelial Cells
Kulshreshtha 
et al. 2013 
[64]
Proinflammatory 
role of epithelial 
cell–derived 
exosomes in allergic 
airway inflammation
Investigate the 
mechanisms of how 
structural and immune 






During asthmatic inflammation, 
epithelial cell–derived exosomes 
stimulated by IL-13 can induce 
enhanced proliferation and 
chemotaxis of undifferentiated 
macrophages in the lungs.







epithelial cells in 
vitro and in vivo
Investigate sources of TF 
within the lungs and 






TF mRNA expression and TF-
bearing exosomes secreted by 
mechanically stressed bronchial 
epithelial cells is a potential key 










pathway in severe 
asthma
Evaluate the effects of 
bronchial fibroblast-
derived exosomes on 




Through modulation of epithelial 
cell proliferation, fibroblast-
derived exosomes contribute to 
airway remodelling in severe 
asthma.
Mesenchymal cells






of regulatory T cells 
in asthma
Investigated MSC derived 
exosomes’ 
immunomodulation effect 




MSC exosomes upregulated IL-10 
and TGF- β1 from PBMCs, thus 
promoting proliferation and 
immune-suppression capacity of 
Tregs. 





stromal cells and 
their extracellular 
vesicles act 





Evaluate whether EVs 
obtained from AD-MSC 
provide therapeutic effects 








Human AD-MSCs and EVs 
effectively reduced eosinophil 
counts and modulated airway 
remodeling, but the effects of 
EVs on T-cells were not 
significant.
















Determine the effects of 
xenogeneic administration 
of CM or EVs from human 
bone marrow‐derived 









Systemic administration of CM 
and EVs from both hMSCs and 
mMSCs is more effective than the 
cells themselves in reducing 
Th2/Th17‐mediated airway 
hyperresponsiveness and lung 
inflammation.








































































Unique Lipid Signatures 
of Extracellular Vesicles 
from the Airways of 
Asthmatics
Determine the lipid 
composition and presence of 
specific lipid mediators in 




Alterations in the 
composition of lipid 
mediators driven by EVs may 
lead to chronic airway 










in cystic fibrosis, 
primary ciliary 
dyskinesia and asthma
Study the similarities and 
differences in 
proteomic content of BALF-




Proteomic profiles of 
exosomes isolated from BALF 
of CF, PCD and asthmatic 
patients suggest that they 
carry different pro-
inflammatory proteins, but 
are involved in the 









contribute to cytokine 
and leukotriene 
production in allergic 
asthma
Explore the LT biosynthetic 
capacity, phenotypic and 
functional characteristics of 




BALF exosomes from 
asthmatics increases 
cytokine and 
LTC4 generation in airway 
epithelium and may 






Extracellular Vesicles in 
the Lungs Control 
Immune Homeostasis 
of the Respiratory Tract 
via TGF-β1 and IL-10
Investigate the role of EVs 
in regulating the immune 




EVs isolated from WT mice 
BALF contains TGF-β1 and 
IL-10 which are involved in 
controlling the immune 








fluid exosomes in 
asthmatic patients
Investigate whether asthma 
and following subway air 




Healthy subjects and patients 
with unprovoked, mild, 
stable asthma showed 






bronchoalveolar fluid of 
tolerized mice prevent 
allergic reaction
Determine the effects of 
allergen-specific exosomes 
from tolerized mice on the 
development of allergen-
induced allergic response 




Induction of tolerance and 
protection against allergic 












Investigate whether the 
preventative effects against 
sensitization to a specific 
allergen, Ole e 1, can be 





Tolerized exosomes specific 
to Ole e 1 prevented allergic 
sensitization to an unrelated 
allergen. This "bystander 
suppression" may have 





Selective release of 
miRNAs via 





Determine the biological 






Pathogenesis of allergic 
airway inflammation 
following HDM exposure may 
involve the increase of EVs in 
the airways, and the 






are key intercellular 
mediators in the 
development of 
immune dysfunction to 
allergens in the airways
Investigate whether the 
development of airway 
immune dysfunction in 
response to allergens 







As key intercellular 
communicator, LPS 
inhalation induced EVs 
facilitate the development of 
airway immune dysfunction 
in response to inhaled 
LPS‐containing allergens.































































Table 6. Summary of studies on exosomes derived from serum, nasal lavage fluid 
and exhaled breath condensate
Author, Year 
[Ref] Title Aim Type Conclusion
Serum
Almqvist et al. 
2008 [84]
Serum-derived exosomes 
from antigen-fed mice 
prevent allergic 
sensitization in a model 
of allergic asthma
Investigate whether 
tolerosomes can protect 
against allergic 
sensitization in a mouse 




Naïve recipient mice 
administered 
intraperitoneally with 
serum or isolated serum 
exosomes of OVA-fed 
mice nullified allergic 
sensitization in the 
recipients.
Gao et al. 2017 
[85]
Post-Effect of Air Quality 
Improvement on 
Biomarkers for Systemic 
Inflammation and 
Microparticles in Asthma 
Patients After the 2008 
Beijing Olympic Games: 
a Pilot Study
Investigate whether air 
quality improved 
systemic inflammation 
and affected circulating 
MVs in asthmatic patients 





mechanisms of ASM 
dysfunction in asthmatics 
might involve circulating 
MVs.
Nasal Lavage Fluid
Lässer et al. 2016 [86]
Exosomes in the 
nose induce immune 
cell trafficking and 
harbour an altered 





derived exosomes from 
asthmatics/CRS 
patients and healthy 
subjects to determine 
whether they could 




In subjects with airway 
diseases, nasal exosomes 
could contribute to 
increased risk of infections 
by stimulating the 
migration of innate immune 
cells and decreasing 




Sinha et al. 2013 [87]
Exosome-enclosed 
microRNAs in exhaled 
breath hold potential 
for biomarker 




miRNAs contained in 
EBC-derived exosomes 
could be an ideal 




The secretion and contents 
of EBC-derived exosomes 
are highly regulated and 
could reflects ongoing 
biological processes.































































Table 7. The role of each EVs separated by cell origin in asthma. ✓ suggests evidence 
supporting hypothesis. - suggests there is no evidence supporting the hypothesis. Reference 
to the study is in parenthesis [n].




Mast cells ✓ [24] - ✓ [25, 26]  
Eosinophil ✓ [30, 31]    ✓ [32] -
Neutrophils - ✓ [37]  -
B cells ✓ [43] - -
T cells ✓ [51, 52]  - -
DCs ✓ [19, 54]  - -
MDRC ✓ [57]  - -
Epithelial cells ✓ [64]  ✓ [65]  -
Fibroblasts - ✓ [68]  -
MSC - - ✓ [71-73]  
































































Figure 1. Mechanisms of Airway Inflammation in Asthma. In the sensitisation phase, 
DCs present antigen to T cells in the lymph nodes causing differentiation of naïve T cells. The 
Th1 response leads to cell mediated immunity and neutrophilic inflammation. Th2 cytokines 
cause class switching of B cells to produce IgE (mainly through IL-4), and recruitment of 
immune cells including eosinophil (mainly through IL-5). In the early asthmatic response, 
allergen binding to IgE receptors on mast cells causing degranulation and release of 
histamine, proteases, tumour necrosis factor (TNF), lipid mediators and other proteins. This 
leads to immediate hypersensitivity and bronchoconstriction. In the late asthmatic response, 
mast cells release chemokines and cytokines which recruit eosinophil, basophils (not shown), 
and T helper cells to the local mucosa. Both mast cells and Th2 cytokines leads to eosinophilia. 
Eosinophils degranulate to release eosinophil granule proteins. These proteins cause 
bronchoconstriction along with damage towards the epithelial layer. Ongoing inflammatory 
responses in the airway can lead to smooth muscle dysfunction and airway remodelling.
Figure 2: Summary of Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow diagram. The process involves identification, screening, eligibility and studies 
included. Sources were retrieved from two databases (PubMed and EMBASE) with no 
restrictions to year, status or languages. 
Figure 3: The number of studies on EVs of known origin and Asthma Based on Year Published. 
The first study was published in 2001, with numbers of publications increasing yearly until 
2018, when nine studies were published.
Figure 4: The number of studies on EVs and Asthma Based on Origin of EVs.  MDRC: Myeloid-
derived regulatory cells, BALF: Bronchoalveolar lavage fluid, NLF: Nasal lavage fluid, EBC: 
Exhaled breath condensate.































































Figure 1. Mechanisms of Airway Inflammation in Asthma. In the sensitisation phase, DCs present antigen to 
T cells in the lymph nodes causing differentiation of naïve T cells. The Th1 response leads to cell mediated 
immunity and neutrophilic inflammation. Th2 cytokines cause class switching of B cells to produce IgE 
(mainly through IL-4), and recruitment of immune cells including eosinophil (mainly through IL-5). In the 
early asthmatic response, allergen binding to IgE receptors on mast cells causing degranulation and release 
of histamine, proteases, tumour necrosis factor (TNF), lipid mediators and other proteins. This leads to 
immediate hypersensitivity and bronchoconstriction. In the late asthmatic response, mast cells release 
chemokines and cytokines which recruit eosinophil, basophils (not shown), and T helper cells to the local 
mucosa. Both mast cells and Th2 cytokines leads to eosinophilia. Eosinophils degranulate to release 
eosinophil granule proteins. These proteins cause bronchoconstriction along with damage towards the 
epithelial layer. Ongoing inflammatory responses in the airway can lead to smooth muscle dysfunction and 
airway remodelling. 






























































































Additional records identified 
through other sources
(n = 0)
Records after duplicates removed
(n = 260)
Records excluded because 
reviews or not 
relevant to research 
question
(n = 197)
Full-text articles assessed 
for eligibility
(n = 63)
Full-text articles excluded, 
with reasons
(n = 29)
 Not EVs: 3
 Not asthma: 6
 Not in English: 4
 Microbial EVs: 4
 Reviews: 12





































































Figure 3: The number of studies on EVs of known origin and Asthma Based on Year Published. The first 
study was published in 2001, with numbers of publications increasing yearly until 2018, when nine studies 
were published. 
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Figure 4: The number of studies on EVs and Asthma Based on Origin of EVs.  MDRC: Myeloid-derived 
regulatory cells, BALF: Bronchoalveolar lavage fluid, NLF: Nasal lavage fluid, EBC: Exhaled breath 
condensate. 
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